Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families

A series of thienopyridine ureas with dual inhibitory activity against KDR and Aurora B kinase has been identified. Compound 2 (ABT-348) of this series is currently undergoing Phase I clinical trials in solid and hematological cancer populations.